Phase 2 Endometrial Cancer Trial, Recruiting NCT06093438 Sponsor: Tianjin Medical University Cancer Institute and Hospital Condition: Endometrial Cancer
Back to Endometrial Cancer

Phase 2 Endometrial Cancer Trial, Recruiting

NCT06093438
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been newly diagnosed with locally advanced cervical cancer (not yet treated) and the diagnosis has been confirmed by a tissue sample (biopsy)
  • Your cancer is at a specific advanced stage (2019 FIGO stage IIIB–IVA), or if stage IIIC, the affected lymph nodes must measure at least 1.5 cm in size
  • You are generally active and able to carry out daily activities with little or no restriction (confirm with trial site)
  • Your doctors expect you to live for more than 6 months
  • You are considered well enough to receive combined chemotherapy and radiation treatment
  • You do not have any obvious active or significant bleeding
  • Your blood counts and kidney and liver function are within acceptable ranges (confirm with trial site)
  • You do not have any other current cancer diagnosis
  • If you could become pregnant, you have tested negative for pregnancy and agree to use reliable contraception throughout the trial
  • You are willing to sign a consent form agreeing to take part

Who may not be able to join:

  • You have been diagnosed with another cancer at the same time
  • Your cervical cancer has spread to distant parts of the body or has come back after previous treatment
  • You have already received any treatment for your cervical cancer before joining
  • You have serious ongoing conditions such as poorly controlled diabetes, high blood pressure, or a current active infection
  • Your blood counts, liver function, or kidney function fall outside the acceptable ranges required for the trial (confirm with trial site for specific values)
  • You have significant heart problems, such as irregular heartbeat, reduced heart function, or serious heart valve disease
  • You have a mental health condition that is not currently under control
  • You are pregnant or currently breastfeeding
  • You are already taking part in another clinical trial
  • The lead doctor on the trial considers you unsuitable for any other reason (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jie Chen, Tianjin Medical University Cancer Institute and Hospital

Phone: +86-18522123151

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Registry
ClinicalTrials.gov
Start date
1 November 2023
Est. completion
1 November 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Overall response rate; Volume changes of core radiation targets and irradiated normal tissues after induction treatment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov